Mirza Hasan, MD
Infectious Disease · Dallas, TXNPI 1255369815
Payments from drug & device makers
Across 310 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- Merck$787
- Johnson & Johnson$683
- AbbVie$549
- Shionogi Inc$539
- Paratek Pharmaceuticals, Inc.$433
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,031100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 63 | $1,400 |
| Merck | 43 | $787 |
| Johnson & Johnson(2 entities) | 40 | $683 |
| AbbVie | 28 | $549 |
| Shionogi Inc | 28 | $539 |
| Paratek Pharmaceuticals, Inc. | 26 | $433 |
| Insmed, Inc. | 10 | $238 |
| Cumberland Pharmaceuticals, Inc. | 11 | $182 |
| AstraZeneca | 7 | $162 |
| Gilead | 7 | $150 |
| Melinta Therapeutics, LLC | 8 | $143 |
| Aimmune Therapeutics, Inc. | 6 | $132 |
| La Jolla Pharmaceutical Company | 5 | $114 |
| Theratechnologies Inc. | 6 | $111 |
| Kvk-tech, Inc. | 4 | $81 |
| Astellas Pharma US Inc | 3 | $73 |
| Mayne Pharma Commercial LLC | 3 | $57 |
| Ferring Pharmaceuticals Inc. | 2 | $54 |
| Pfizer | 4 | $47 |
| Dynavax Technologies Corporation | 3 | $43 |
| Nabriva Therapeutics, PLC | 2 | $27 |
| Seqirus USA Inc | 1 | $26 |
How this compares
$6,031 in reported general payments places this provider in the 75th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 11 | $11,391 |
| Vancomycin Hcl | 18 | $1,884 |
| Cefepime Hcl | 11 | $1,043 |
| Pantoprazole Sodium | 20 | $793 |
| Levothyroxine Sodium | 60 | $782 |
| Metoprolol Succinate | 20 | $484 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 13 | $448 |
| CeftriaxoneCeftriaxone Sodium | 11 | $427 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 17 | $419 |
| Montelukast Sodium | 25 | $381 |
| Famotidine | 19 | $375 |
| Losartan Potassium | 19 | $331 |
| Amlodipine Besylate | 34 | $283 |
| Tamsulosin Hcl | 22 | $238 |
| Allopurinol | 19 | $212 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Dallas
- Mezgebe BerheDallas$11M
- Mamta JainDallas$3.7M
- Elizabeth RaceDallas$1.5M
- David GreenbergDallas$1.2M
- Roger BedimoDallas$976K
- Theodoros KelesidisDallas$715K
- Uriel SandkovskyDallas$616K
- Jeremy ChowDallas$500K
- Satish MocherlaDallas$417K
- Edward DominguezDallas$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.